Drug Trial Radar · NCT04704713
Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)
Last checked: Nov 20, 2026Latest source record: Mar 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
May 5, 2010
Primary completion
Dec 9, 2010
Sponsor
- Lead sponsor
- Clinuvel Pharmaceuticals LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jan 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was to evaluate the safety and efficacy of afamelanotide in patients suffering from polymorphic light eruption (PLE).
Conditions
- Polymorphic Light Eruption
Interventions
AfamelanotideDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Severity of PLE Related Pruritus Recorded Using an 11-point Likert ScaleTime frame: From Day 0 to Day 120
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.